News & Events

  • RNA Leaders Europe Congress 2024

    When: Mar. 13th, 2024 to Mar. 14th, 2024
    Where: Basel, Switzerland

    Anima’s Vice President of Business Development, Gal Gur, Ph.D., will participate in the upcoming congress during in two roundtable sessions, both focused on the topic of, “Target selection – lessons learned from small molecules RNA Biology,” to discuss her learnings from working on target selection in the mRNA biology space. The sessions are taking place on March 14th at 9:05 AM and 9:50 AM CET. Additionally, Gal will give a presentation titled, "Bringing AI to mRNA Biology for the Discovery of mRNA Drugs and Targets,” on March 14th at 11:20 AM CET. The presentation will discuss how Anima’s mRNA Lightning platform can visualize the complete mRNA life cycle from multiple disease models using high content - high throughput mRNA imaging technologies and how it can decode mRNA biology underlying disease phenotypes using AI. She will also discuss the platform’s applications in drug and target discovery, mRNA vaccine optimization, and RNA-based drug optimization with examples and case studies in oncology and immunology.

    The RNA Leaders Europe Congress program features scientific tracks covering in-depth development strategies, trends, and technologies across the entire long and small RNA spectrum. The congress provides an opportunity to join key stakeholders to examine new data and case studies, assess the latest technologies and their potential, and forge the collaborations needed to bring new discoveries to market.

    Download Press Release »

  • Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis

    When: Feb. 7th, 2024

    Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate. This drug operates through a novel mRNA biology mechanism of action, opening new avenues for treating Idiopathic Pulmonary Fibrosis (IPF) patients.

    Utilizing its mRNA Lightning™ Platform, Anima has successfully identified a preclinical candidate operating through a novel mRNA biology mechanism of action, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts. By inhibiting myofibroblasts' deposition of extracellular matrix, this candidate demonstrates substantial potential in mitigating fibrotic diseases. The candidates' oral efficacy in mouse IPF models demonstrates a remarkable safety-to-activity margin and superiority to standard-of-care drugs. It significantly reduces collagen production and fibrotic biomarkers in cells and tissue explants derived from IPF patients. Its clean in vitro ADMET profile further underscores its promise as a breakthrough in fibrotic disease treatment.

    "This recent achievement further validates our approach, “said Yochi Slonim, co-founder and CEO of Anima. “Our platform's ability to visualize mRNA biology and decode it with AI technology enables a deeper understanding of disease mechanisms, identification of novel targets, and discovery of drugs that can directly modify the disease phenotype."

    Anima’s unique approach is validated by its strategic partnerships with big pharma, including AbbVie, Takeda, and Eli Lilly, and a broad pipeline of discovery programs across Immunology, Oncology, and Neuroscience. Anima’s LightON mRNA | mRNA Biology Masterclass series has become a central forum for over 1,500 industry and academic experts presenting the latest advances in mRNA biology and its applications to drug discovery.

    Download Press Release »

  • 6th Annual RNA-Targeted Drug Discovery and Development Summit

    When: Dec. 12th, 2023 to Dec. 14th, 2023
    Where: Boston, MA

    Anima Biotech will participate in the 6th Annual RNA-Targeted Drug Discovery and Development Summit taking place in Boston, MA from December 12-14, 2024. Our Vice President of Business Development, Gal Gur, Ph.D., will participate on a panel titled, “Overcoming Key Challenges to Improve Drug Design & Discovery for Novel Approaches,” on Wednesday, December 13th at 3:30 PM ET and will also give a presentation titled, “AI in mRNA Biology: Small Molecule Drug & Target Discovery,” on Thursday, December 14th at 12:30 PM ET.

    Download Press Release »

    Visit the conference website »

  • BioSpace Webinar | mRNA is Never Naked, Exploring RBP Target Space & Therapeutic Opportunities

    When: Nov. 14th, 2023

    Anima presents its third webinar, a part of its exclusive LightON mRNA | mRNA Biology Masterclass series. The mRNA Biology Masterclasses latest webinar, titled, “mRNA is Never Naked, Exploring RBP Target Space & Therapeutic Opportunities,” in partnership with BioSpace will take place on November 14th at 11:00 AM EST. 

    Download Press Release »

    Register to the webinar »

  • 5th Annual Small Molecules Targeting RNA

    When: Sep. 27th, 2023

    Anima Biotech will participate in the 20th Anniversary event for Discovery on Target, as part of the 5th Annual Small Molecules Targeting RNA conference taking place in Boston, MA, and virtually. Our co-founder and Chief Scientific Officer, Iris Alroy, will give a remote presentation titled, Discovery of Small Molecules Regulating mRNA and Identification of Novel mRNA Regulatory Target Proteins on September 27th at 8:00 am ET.

    Visit the conference website »

  • GEN webinar | Technologies developed to study mRNA life cycle

    When: Sep. 12th, 2023

    Join our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D. as she and other experts delve into innovative technologies that harness mRNA regulation to advance future therapeutics - from splicing and export to localization, degradation, stabilization, and translation.

    Download Press Release »

    Register to the webinar »

  • RNA Leaders USA 2023

    When: Sep. 6th, 2023 to Sep. 7th, 2023
    Where: Boston, MA

    Anima Biotech will participate in the RNA Leaders USA Congress, as part of the Small Molecules Targeting RNA track of the conference, being held in Boston, MA. Our Senior Director of Corporate Development and Marketing, Clara Assouline, will give a presentation titled, “mRNA Lightning | Discovery of small molecule mRNA drugs and novel mRNA biology targets”, on September 6th at 4:50 pm ET.

    Visit the conference website »

  • BIO International Convention 2023

    When: Jun. 5th, 2023 to Jun. 8th, 2023
    Where: Boston, MA

    Anima Biotech will be attending this year’s BIO International Convention. Our chief business officer, Kevin Pong, Ph.D., is looking forward to connecting with other industry experts. Additionnaly, he will give a corporate presentation on June. 5th at 3:45 P.M. EDT highlighting our unique approach to the discovery of small molecule mRNA drugs.

    Visit the conference website »

  • Oxford Global Discovery Europe

    When: Jun. 6th, 2023 to Jun. 7th, 2023
    Where: Berlin, Germany

    Anima Biotech will participate in the Oxford Global Discovery Europe event as part of Identification and Validation of Novel Targets track of the Conference held in Berlin, Germany. Our head of discovery, Yoni Sheinberger, Ph.D., will give a presentation titled, “mRNA Lighting Platform | Discovery Of mRNA Biology Modulators and Their Mechanisms of Action,” on June 6th at 12:05 p.m. CST.

    Visit the conference website » »

  • Locust Walk RNA Innovation Conference

    When: May. 9th, 2023
    Where: Virtual

    Anima Biotech has been invited to give a presentation during the Locust Walk RNA innovation event as part of the RNA-Targeting SMOLs track of the Conference held virtually on May 9th. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will give a presentation titled, “Advancing mRNA Lightning™ for the discovery of small molecule mRNA modulators and their mechanisms of action using phenotypic screening and AI driven MOA elucidation” from 1:20 – 1:40 AM ET. 

    Download Press Release »

    Visit the organization website »

Pages